Optimizing management of treatment-na&iuml;ve and treatment-experienced HIV+ patients: the role of maraviroc

Optimizing management of treatment-na&iuml;ve and treatment-experienced HIV+ patients: the role of maraviroc

Eva Poveda, Vincent SorianoDepartment of Infectious Diseases, Hospital Carlos III, Madrid, SpainAbstract: Maraviroc is the first CCR5 antagonist approved for the treatment of HIV-1 infection. It specifically inhibits the replication of R5 viruses by blocking viral entry. HIV-1 tropism can be estimat...

Full description

Bibliographic Details
Main Authors:	Eva Poveda, Vincent Soriano
Format:	Article
Language:	English
Published:	Dove Medical Press 2010-03-01
Series:	HIV/AIDS: Research and Palliative Care
Online Access:	http://www.dovepress.com/optimizing-management-of-treatment-naiumlve-and-treatment-experienced--a4111

Similar Items

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
by: Gonzalez-Serna A, et al.
Published: (2016-01-01)

Maraviroc (Celsentri) in HIV treatment
by: Viola Sacchi
Published: (2008-01-01)

Gut bacterial profile in patients newly diagnosed with treatment-na&iuml;ve Crohn&#39;s disease
by: Ricanek P, et al.
Published: (2012-09-01)

Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy
by: Corado KC, et al.
Published: (2018-11-01)

An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients
by: Putcharoen O, et al.
Published: (2013-09-01)

Effectiveness and cost of treatment with maraviroc in HIV infection
by: Viola Sacchi, et al.
Published: (2009-01-01)

Economic modeling in HIV for maraviroc in France in treatment experienced patients. Results from the ARAMIS 2011 model
by: Despiegel Nicolas, et al.
Published: (2012-05-01)

Histopathological Pattern of Kidney Diseases Among HIV-Infected Treatment-Naïve Patients in Kano, Nigeria
by: Abdu A, et al.
Published: (2021-05-01)

Undernutrition in ART-naïve Nigerian children
by: Shantakumari N, et al.
Published: (2015-07-01)

Magnitude of cytopenias among HIV‑infected children in Bahir Dar, northwest Ethiopia: a comparison of HAART-naïve and HAART‑experienced children
by: Tsegay YG, et al.
Published: (2017-02-01)

Increased burden and severity of metabolic syndrome and arterial stiffness in treatment naïve HIV+ patients from Cameroon
by: Ngatchou W, et al.
Published: (2013-09-01)

Maraviroc – a CCR5 antagonist for the treatment of HIV-1 infection
by: Elna eVan Der Ryst
Published: (2015-06-01)

Progressive multifocal leukoencephalopathy developing in a fludarabine na&iuml;ve patient with chronic lymphocytic leukemia
by: Melissa G Ooi, et al.
Published: (2009-01-01)

Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
by: Cameli P, et al.
Published: (2024-03-01)

An observational study of bimatoprost 0.01% in treatment-na&iuml;ve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
by: Nixon DR, et al.
Published: (2012-12-01)

Cardiac Abnormalities of People Living with HIV: A Comparative Study Between HAART Experience and Treatment Naïve Groups in Ghana
by: Owusu I K, et al.
Published: (2022-06-01)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
by: Restelli U, et al.
Published: (2017-06-01)

Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens
by: A V Kravchenko
Published: (2013-11-01)

Acceptability and efficacy of interactive short message service intervention in improving HIV medication adherence in Chinese antiretroviral treatment-naïve individuals
by: Ruan Y, et al.
Published: (2017-02-01)

Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease – associations with disease phenotype, treatment, and outcome
by: Olbjørn C, et al.
Published: (2019-01-01)

Adherence to insulin treatment in insulin-naïve type 2 diabetic patients initiated on different insulin regimens
by: Gogas Yavuz D, et al.
Published: (2015-08-01)

Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in na&iuml;ve myopic choroidal neovascularization
by: Bergamini F, et al.
Published: (2012-11-01)

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
by: Laine I, et al.
Published: (2017-11-01)

Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients
by: Freeman L, et al.
Published: (2021-01-01)

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
by: Jintanat Ananworanich, et al.
Published: (2015-04-01)

Maraviroc: a review of its use in HIV infection and beyond
by: Woollard SM, et al.
Published: (2015-10-01)

Identification of NS5B Resistance-Associated Mutations in Hepatitis C Virus Circulating in Treatment Naïve Vietnamese Patients
by: Nguyen TK, et al.
Published: (2022-04-01)

Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary Disease
by: Takahashi K, et al.
Published: (2021-12-01)

Poor immunological recovery among severely immunosuppressed antiretroviral therapy-naïve Ugandans
by: Nanzigu S, et al.
Published: (2013-12-01)

Sleep Disturbances and Associated Factors in Drug-Naïve Patients with Parkinson’s Disease
by: Zhong M, et al.
Published: (2021-12-01)

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.
by: Marilyn Lewis, et al.
Published: (2018-01-01)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
by: Christophe Rodriguez, et al.
Published: (2015-01-01)

The Discovery and Exploratory Development of Maraviroc (UK-427,857): A Novel CCR5 Antagonist for the Treatment of HIV
by: Hitchcock CA
Published: (2005-12-01)

Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data
by: Mannino DM, et al.
Published: (2018-05-01)

A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population
by: Yazici Y, et al.
Published: (2018-10-01)

A retrospective database analysis of insulin use patterns in insulin-na&iuml;ve patients with type 2 diabetes initiating basal insulin or mixtures
by: Machaon MK Bonafede, et al.
Published: (2010-06-01)

A Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Biomarkers and Treatment Outcome
by: Vadalà M, et al.
Published: (2020-09-01)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
by: Schols Dominique, et al.
Published: (2011-10-01)

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient
by: Poizot-Martin Isabelle, et al.
Published: (2010-05-01)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
by: Margaret O. Ilomuanya, et al.
Published: (2020-11-01)